Current Cardiology Reports

, 15:370

18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis

Authors

  • Hicham Skali
    • Department of Radiology, Division of Nuclear Medicine and Molecular imaging
    • Department of MedicineCardiovascular Division
  • Allison R. Schulman
    • Department of MedicineBrigham and Women’s Hospital, Harvard Medical School
    • Department of Radiology, Division of Nuclear Medicine and Molecular imaging
    • Department of MedicineCardiovascular Division
Nuclear Cardiology (V Dilsizian, Section Editor)

DOI: 10.1007/s11886-013-0370-6

Cite this article as:
Skali, H., Schulman, A.R. & Dorbala, S. Curr Cardiol Rep (2013) 15: 370. doi:10.1007/s11886-013-0370-6
Part of the following topical collections:
  1. Topical Collection on Nuclear Cardiology

Abstract

Cardiac involvement portends a poor prognosis in patients with sarcoidosis. However, due to the nonspecific clinical manifestations of the disease, patchy myocardial involvement, and the limited diagnostic yield of diagnostic tests, early diagnosis of cardiac sarcoidosis has been exceedingly difficult. As a result, there is no standardized approach for the early diagnosis of cardiac sarcoidosis. Imaging modalities that can both identify disease and predict response to therapy are paramount to improve management of cardiac sarcoidosis. 18F-FDG PET has many practical advantages in assessing disease activity and monitoring treatment response in patients with cardiac sarcoidosis. Accumulating data support the growing role of 18F-fluorodeoxyglucose (18F-FDG) PET in the diagnosis and risk stratification of patients with cardiac sarcoidosis.

Keywords

Cardiac sarcoidosis 18F-FDG PET Myocardial sarcoidosis

Copyright information

© Springer Science+Business Media New York 2013